Type 2 diabetes mellitus (T2DM) is a chronic progressive metabolic condition characterized by insulin resistance and decreased beta‐cell function.1 Patients with T2DM suffer from either one or several metabolic abnormalities, such as obesity, increased endogenous glucose output, compromised insulin action and insulin secretion dysfunction.2, 3, 4 This condition places patients at an elevated risk of developing cardiovascular diseases, myocardial infarctions, stoke and elevated blood pressure along with many other potential health impediments.5, 6. This evidence concerns the gene INS and diabetes mellitus.